Acetaminophen
This article was originally published in The Tan Sheet
Executive Summary
Questions of whether analgesic depletes glutathione and should carry label warning against excessive use by HIV-infected individuals "are being addressed" in FDA's evaluation of acetaminophen toxicity "in various populations, in specific clinical situations and at different dosages," agency says. In an interim response to a petition from Leonore Herzenberg, PhD, Stanford University, requesting such a warning, FDA notes its analysis "includes a review of the possible need for revised labeling." FDA is examining more extensive ways to inform consumers of acetaminophen risks and limit OTC access. Agency also is reviewing McNeil's request to expand age groups for OTC pediatric dosing instructions
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning